http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Chie Sato (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Tetsuya Kawano,Naohisa Miyakoshi,Yuji Kasukawa,Michio Hongo,Hiroyuki Tsuchie,Chie Sato,Masashi Fujii,Masazumi Suzuki,Manabu Akagawa,Yuichi Ono,Yusuke Yuasa,Itsuki Nagahata,Yoichi Shimada 대한골다공증학회 2017 Osteoporosis and Sarcopenia Vol.3 No.4
Objectives: Glucocorticoid (GC) treatment inhibits activation of runt-related transcription factor 2 (Runx2), which is essential for osteoblast differentiation from stem cells. As a result, GC treatment results in bone loss, GC-induced osteoporosis (GIO), elevated fracture risk, and delayed bone healing. Bisphosphonates such as alendronate (ALN) are recommended for treating or preventing GIO, and lowintensity pulsed ultrasound (LIPUS) facilitates fracture healing and maturation of regenerated bone. Combined therapy with ALN and LIPUS may stimulate cancellous bone healing in GIO rats. Here, we examined the effect of ALN and LIPUS on cancellous bone osteotomy repair in the proximal tibia of GIO rats. Methods: Prednisolone (10 mg/kg body weight/day) was administered for 4 weeks to induce GIO in 6- month-old female Sprague-Dawley rats. Tibial osteotomy was then performed and daily subcutaneous injection of ALN (1-mg/kg body weight) was subsequently administered alone or in combination with LIPUS (20 min/day) for 2 or 4 weeks. Results: ALN significantly increased bone mineral density (BMD) at 2 and 4 weeks, and ALN þ LIPUS significantly increased BMD at 4 weeks. Bone union rates were significantly increased after 2 and 4 weeks ALN and ALN þ LIPUS treatment. Lastly, ALN and ALN þ LIPUS significantly increased the proportion of Runx2 positive cells at 4 weeks. Conclusions: ALN monotherapy and combined ALN and LUPUS treatment augmented BMD and stimulated cancellous bone repair with increased Runx2 expression at the osteotomy site in GIO rats. However, the combined treatment had no additional effect on cancellous bone healing compared to ALN monotherapy. © 2017 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
-
Kentaro Ohuchi,Naohisa Miyakoshi,Yuji Kasukawa,Toyohito Segawa,Hayato Kinoshita,Chie Sato,Masashi Fujii,Yoichi Shimada 대한골다공증학회 2019 Osteoporosis and Sarcopenia Vol.5 No.4
Objectives: The purpose of this study is to evaluate the effects of teriparatide (TPTD) on bone mineral density (BMD), bone strength, and bone quality in Akita mouse models of diabetes mellitus. Methods: Twelve-week-old female Akita mice and control mice (C57/BL/6NCrSlc) were divided into 4 groups: control mice treated with vehicle (n ¼ 7) or TPTD (n ¼ 6); and Akita mice treated with vehicle (n ¼ 6) or TPTD (n ¼ 7). TPTD or vehicle was administered subcutaneously 3 times a week for 8 weeks. Blood glucose, serum sclerostin, total tibial BMD, femoral shaft bone strength, and bone quality using Fourier-transform infrared spectroscopy imaging were evaluated. Results: No significant differences in serum sclerostin levels were evident among these groups after 8 weeks of treatment. TPTD significantly increased BMD in control mice (þ12.7%, P ¼ 0.02) and Akita mice (þ29.2%, P ¼ 0.001) compared with vehicle. Maximum load and stiffness were significantly higher in Akita mice treated with TPTD than in Akita mice treated with vehicle (þ56.6%, P ¼ 0.03 and þ 90.5%, P ¼ 0.02, respectively). On Fourier-transform infrared spectroscopy imaging, the mineral/matrix ratio was significantly lower in Akita mice treated with vehicle than in control mice (12.2%, P ¼ 0.02), and TPTD treatment significantly increased the mineral/matrix ratio (P ¼ 0.003). Conclusions: TPTD thus improved BMD and bone strength in both control mice and Akita mice, with improvements in the mineral/matrix ratio among Akita mice.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
